{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:06:57Z","timestamp":1791209217511,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Res Methodol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Individual patient-level survival data (IPD) is required for various types of medical research, such as meta-analyses and cost-effectiveness analyses. As IPD from clinical trials are usually not publicly available, secondary data utilization relies on IPD reconstruction from published Kaplan-Meier (KM) plots. In general, the established toolchains for IPD reconstruction are cumbersome and rarely offer possibilities to assess reconstruction accuracy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implementation<\/jats:title>\n                    <jats:p>\n                      We have therefore developed V-Exploder, an academic, non-profit, data-local tool that integrates the complete workflow of IPD reconstruction into a single browser application (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.v-exploder.com\" ext-link-type=\"uri\">www.v-exploder.com<\/jats:ext-link>\n                      ). Implemented methods include the iterative algorithms described by Guyot et al. and Rogula et al., and a novel, direct method for the positioning of individual events and censorings. A key feature of V-Exploder is its immediate visual feedback: recreated KM graphs are continuously constructed and superimposed onto the original figure. This enables more precise IPD reconstruction than previously possible.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a study to evaluate the IPD reconstruction performance of V-Exploder. Ten investigators each reconstructed data from four of a total of twelve figures, each showing the survival of two randomly generated cohorts (20, 50, 100, or 200 subjects in each cohort). Metrics frequently used in survival analysis were calculated for the original and reconstructed data. Median absolute errors (AE), their interquartile ranges (IQR), and root square mean errors (RMSE) are reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Survival metrics from reconstructed IPD showed high similarity to metrics calculated from the reference data across all datasets, investigators and used methods of IPD reconstruction. Regarding log HRs, median AE (IQR) &amp; RMSE with the direct, Rogula, and Guyot method were 5.93\u2009\u00d7\u200910\n                      <jats:sup>\u2212\u20094<\/jats:sup>\n                      (7.61\u2009\u00d7\u200910\n                      <jats:sup>\u2212\u20095<\/jats:sup>\n                      , 1.65\u2009\u00d7\u200910\n                      <jats:sup>\u2212\u20093<\/jats:sup>\n                      ) &amp; 6.26\u2009\u00d7\u200910\n                      <jats:sup>\u2212\u20093<\/jats:sup>\n                      , 5.28\u2009\u00d7\u200910\n                      <jats:sup>\u2212\u20094<\/jats:sup>\n                      (3.21\u2009\u00d7\u200910\n                      <jats:sup>\u2212\u20095<\/jats:sup>\n                      , 2.59\u2009\u00d7\u200910\n                      <jats:sup>\u2212\u20093<\/jats:sup>\n                      ) &amp; 4.05\u2009\u00d7\u200910\n                      <jats:sup>\u2212\u20093<\/jats:sup>\n                      , and 4.17\u2009\u00d7\u200910\n                      <jats:sup>\u2212\u20093<\/jats:sup>\n                      (1.84\u2009\u00d7\u200910\n                      <jats:sup>\u2212\u20093<\/jats:sup>\n                      , 1.96\u2009\u00d7\u200910\n                      <jats:sup>\u2212\u20092<\/jats:sup>\n                      ) &amp; 2.38\u2009\u00d7\u200910\n                      <jats:sup>\u2212\u20092<\/jats:sup>\n                      , respectively. IPD reconstruction validity and reliability were lower with the Guyot method compared to the other methods, especially when used on smaller datasets. However, errors were considered acceptable for most research applications regardless of the method used.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>V-Exploder allows IPD reconstruction from published KM plots with high accuracy and reliability. Given its user-friendly visual interface, V-Exploder will facilitate secondary analysis of survival data and help improving analytic rigor.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12874-026-03036-3","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:16:18Z","timestamp":1791206178000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Visual extraction of individual patient data from published kaplan-meier survival plots using a web-based application offering different reconstruction methods (V-Exploder)"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6207-0237","authenticated-orcid":false,"given":"Fabian","family":"Acker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Ruge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Rost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Heinzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike C.","family":"Althoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khouloud","family":"Kouidri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Stratmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Sebastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian E.","family":"Koschade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"issue":"5","key":"3036_CR1","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/j.1524-4733.2004.75013.x","volume":"7","author":"JJ Caro","year":"2004","unstructured":"Caro JJ, Ishak KJ, Migliaccio-Walle K. Estimating survival for cost-effectiveness analyses: a case study in atherothrombosis. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2004;7(5):627\u201335. https:\/\/doi.org\/10.1111\/j.1524-4733.2004.75013.x.","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res"},{"issue":"4","key":"3036_CR2","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1177\/0272989X16670617","volume":"37","author":"C Williams","year":"2017","unstructured":"Williams C, Lewsey JD, Mackay DF, Briggs AH. Estimation of Survival Probabilities for Use in Cost-effectiveness Analyses: A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic Modeling. Med Decis Mak. 2017;37(4):427\u201339. https:\/\/doi.org\/10.1177\/0272989X16670617.","journal-title":"Med Decis Mak"},{"issue":"1","key":"3036_CR3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s40273-019-00845-x","volume":"38","author":"C Smare","year":"2020","unstructured":"Smare C, Lakhdari K, Doan J, Posnett J, Johal S. Evaluating Partitioned Survival and Markov Decision-Analytic Modeling Approaches for Use in Cost-Effectiveness Analysis: Estimating and Comparing Survival Outcomes. PharmacoEconomics. 2020;38(1):97\u2013108. https:\/\/doi.org\/10.1007\/s40273-019-00845-x.","journal-title":"PharmacoEconomics"},{"key":"3036_CR4","unstructured":"Higgins JP, Li T, Deeks JJ. Chapter 6: Choosing effect measures and computing estimates of effect. Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (Updated August 2024). Cochrane; 2024. https:\/\/training.cochrane.org\/handbook\/current\/chapter-06."},{"issue":"1","key":"3036_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8(1):16. https:\/\/doi.org\/10.1186\/1745-6215-8-16.","journal-title":"Trials"},{"issue":"20","key":"3036_CR6","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1158\/1078-0432.CCR-24-0566","volume":"30","author":"TA Lin","year":"2024","unstructured":"Lin TA, McCaw ZR, Koong A, et al. Proportional Hazards Violations in Phase 3 Cancer Clinical Trials: A Potential Source of Trial Misinterpretation. Clin Cancer Res Off J Am Assoc Cancer Res. 2024;30(20):4791\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-0566.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"23","key":"3036_CR7","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1212\/WNL.0000000000207078","volume":"100","author":"AA Veroniki","year":"2023","unstructured":"Veroniki AA, Seitidis G, Tsivgoulis G, Katsanos AH, Mavridis D. An Introduction to Individual Participant Data Meta-analysis. Neurology. 2023;100(23):1102\u201310. https:\/\/doi.org\/10.1212\/WNL.0000000000207078.","journal-title":"Neurology"},{"issue":"1","key":"3036_CR8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12874-022-01567-z","volume":"22","author":"JJ Zhao","year":"2022","unstructured":"Zhao JJ, Syn NL, Tan BKJ, et al. KMSubtraction: reconstruction of unreported subgroup survival data utilizing published Kaplan-Meier survival curves. BMC Med Res Methodol. 2022;22(1):93. https:\/\/doi.org\/10.1186\/s12874-022-01567-z.","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"3036_CR9","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S1470-2045(24)00722-8","volume":"26","author":"T Olivier","year":"2025","unstructured":"Olivier T, Haslam A, Prasad V. The BREAKING-ICE App: an interactive journey into informative censoring. Lancet Oncol. 2025;26(6):693. https:\/\/doi.org\/10.1016\/S1470-2045(24)00722-8.","journal-title":"Lancet Oncol"},{"issue":"1","key":"3036_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades A, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12(1):9. https:\/\/doi.org\/10.1186\/1471-2288-12-9.","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"3036_CR11","doi-asserted-by":"publisher","first-page":"238146832210776","DOI":"10.1177\/23814683221077643","volume":"7","author":"B Rogula","year":"2022","unstructured":"Rogula B, Lozano-Ortega G, Johnston KM. A Method for Reconstructing Individual Patient Data From Kaplan-Meier Survival Curves That Incorporate Marked Censoring Times. MDM Policy Pract. 2022;7(1):23814683221077643. https:\/\/doi.org\/10.1177\/23814683221077643.","journal-title":"MDM Policy Pract"},{"issue":"1","key":"3036_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","volume":"21","author":"N Liu","year":"2021","unstructured":"Liu N, Zhou Y, Lee JJ. IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2021;21(1):111. https:\/\/doi.org\/10.1186\/s12874-021-01308-8.","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"3036_CR13","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1177\/1536867X1801700402","volume":"17","author":"Y Wei","year":"2017","unstructured":"Wei Y, Royston P. Reconstructing Time-to-event Data from Published Kaplan\u2013Meier Curves. Stata J. 2017;17(4):786\u2013802. https:\/\/doi.org\/10.1177\/1536867X1801700402.","journal-title":"Stata J"},{"issue":"22","key":"3036_CR14","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"The Cancer Genome Atlas Research Network","year":"2013","unstructured":"The Cancer Genome Atlas Research Network. Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia. N Engl J Med. 2013;368(22):2059\u201374. https:\/\/doi.org\/10.1056\/NEJMoa1301689.","journal-title":"N Engl J Med"},{"issue":"3","key":"3036_CR15","first-page":"141","volume":"5","author":"OO Aalen","year":"1978","unstructured":"Aalen OO, Johansen S. An Empirical Transition Matrix for Non-Homogeneous Markov Chains Based on Censored Observations. Scand J Stat. 1978;5(3):141\u201350.","journal-title":"Scand J Stat"},{"issue":"1","key":"3036_CR16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/sim.4780030106","volume":"3","author":"R Simon","year":"1984","unstructured":"Simon R, Makuch RW. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: Application to responder versus non-responder bias. Stat Med. 1984;3(1):35\u201344. https:\/\/doi.org\/10.1002\/sim.4780030106.","journal-title":"Stat Med"}],"container-title":["BMC Medical Research Methodology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12874-026-03036-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-026-03036-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-026-03036-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:32:27Z","timestamp":1791207147000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12874-026-03036-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3036"],"URL":"https:\/\/doi.org\/10.1186\/s12874-026-03036-3","relation":{},"ISSN":["1471-2288"],"issn-type":[{"value":"1471-2288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"assertion":[{"value":"3 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"FA reports having received consulting fees from AstraZeneca, Daiichi-Sankyo, IQVIA, Novartis, and NovoCure, honoraria for presentations from Amgen, AstraZeneca, Johnson&amp;Johnson, and Regeneron, and support for attending meetings from Amgen, AstraZeneca, and Daiichi-Sankyo.FCA reports having received research funding from Novartis and Gilead Sciences, speaker\u2019s honoraria from Roche, Amgen, and MSD, support for attending meetings and\/or travel from Amgen and Johnson &amp; Johnson\/Janssen, and consultant fees from IQVIA and Johnson &amp; Johnson\/Janssen.MS reports financial interests, personal, and advisory board: Lilly: AstraZeneca, Boehringer Ingelheim, Novartis, Takeda, BMS, MSD, Merck, Amgen, Pierre Fabre, Gilead, and Daiichi Sankyo; financial interests, personal, and invited speaker: Roche and GSK; and financial interests, institutional, and research grant: AstraZenecaThe remaining authors report having no competing interests to declare.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"216"}}